Analysis of similar drug labeling: potential medication errors

Lopes, Diana Maria de Almeida; Néri, Eugenie Desirèe Rabelo; Madeira, Lucivaldo dos Santos; Neto, Paulo José de Souza; Lélis, Antônia Rocivânia Araújo; Souza, Thalita Rodrigues de; Oliveira, Alene Barros de; Costa, Liana de Oliveira; Fonteles, Marta Maria de França

doi:10.1016/s0104-4230(12)70161-6

Cited by 8 publications

(7 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some of the causes portrayed in the newspaper texts evidenced the participation of other health professionals involved in the care, regarding the medical prescription, which corroborates with other studies, noting that errors in medical prescription may trigger other errors during the process of medication (3,(26)(27)(28)(29) . The most common prescription-related errors involve drug doses and the frequency of administration (30) .…”

Section: Discussionsupporting

confidence: 85%

Nursing errors in the media: patient safety in the window

et al. 2019

View full text Add to dashboard Cite

Objective: To analyze the nursing errors reported by the journalistic media and interpret the main implications of this communication for the visibility of this problem. Method: Documental research, qualitative, descriptive and exploratory, with data collected in news reports from Brazil and Portugal, analyzed through hermeneutics with resources of Atlas Software. Results: We analyzed 112 news items published between 2012 and 2016 that resulted in six categories: Year - highest occurrence in 2012; Age group of the patient - children; Professional category - nurses; Type of error - medication; Outcome - death; Possible attributed cause - occupational conditions. Final considerations: Nursing mistakes are a challenge for the profession, and the way they are communicated by the media is not very explanatory, contributing to a negative visibility of the profession, and to making society insecure. Improving the way they are served in the media contributes to the visibility of the problem without affecting the professional image.

show abstract

Section: Discussionsupporting

confidence: 85%

Nursing errors in the media: patient safety in the window

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Currently, it is the country that has contributed by far most of the evidence on the topic and prevention strategies, in the field of pediatrics as well [9]. The studies published in the UK [10] and some specific projects in Australia, Brazil, Hong Kong, India, Iran, Israel and South Africa are also noteworthy [11][12][13][14][15][16][17]. Some examples of confusing names recorded were: cefuroxime-cefotaxime-ceftazidime, doxorubicin-daunorubicin-idarubicin and carbamazepineoxcarbazepine-carbimazole, as nonproprietary names [11] and Adderall®-Inderal®, PD-Mox®-PD-Rox®, Clomine®-Clo-zine®, Bioclox®-Biodoxi® and Zyrof®-Zyrop®, as brand names [9,14].…”

Section: Risk Minimization Activitymentioning

confidence: 99%

Prevention strategies to identify LASA errors: building and sustaining a culture of patient safety

Lizano-Díez

Figueiredo-Escribá

Piñero-López

et al. 2020

BMC Health Serv Res

View full text Add to dashboard Cite

Background: Potential look-alike, sound-alike (LASA) errors in outpatient and inpatient prescriptions have been widely described worldwide. However, most strategies of reducing drug name confusion have been only focused on the processes of prescribing and dispensing, often following local rules. Main text: An illustrative recent example about this topic is given: the antidepressant Brintellix® (vortioxetine) (Takeda Pharmaceuticals USA, Inc.) and the antiplatelet medication Brilinta® (ticagrelor) (AstraZeneca LP). Revision of the initiatives that are currently applied to prevent potential LASA errors in different countries around the world and debate about the emerging strategies that could be implemented in short and mid-term. At present, a common policy worldwide on the authorization of unique names for innovative medicines does not exist. The implication of authorities in topdown strategies and the importance of developing an international health policy on the authorization of unique names for innovative medicines are highlighted in the following piece of opinion. Conclusions: Building and sustaining a culture of patient safety should be considered as a global top-down strategy which involved all the elements in the system (regulatory bodies, manufacturers and suppliers). The precedent established by the FDA in prevention strategies to identify and avoid LASA errors has been extremely important and should lead to international discussion. Coordinated international efforts are urgently needed in this area for the sake of patients' safety.

show abstract

“…Furthermore, generic drugs encompass all molecules that contain the same active principle, pharmaceutical formula, dose, administration route, with the same reference for therapeutical purpose and safety [20]. In Brazil, the release of these medicaments into the market brought an increase on the competition between pharmaceutical products [21].…”

Section: Biopharmaceuticals and Biosimilarsmentioning

confidence: 99%

Biopharmaceutical and Biosimilar Products in Brazil: From Political To Biotechnological Overview

Basso¹

2013

J Bioequiv Availab

View full text Add to dashboard Cite

According to the World Health Organization (WHO), one third of the world's population don't have the necessary access to pharmaceutical products, including essential drugs. In Brazil, the Governmental Health System (SUS) distributes some medicaments for free to the population. They were, then, classified into three categories in the country: basic, strategic and specialized components. Among these categories, the last one is highlighted due to the expensive costs of its products, which are essential for the treatment of rare and specific diseases. For this reason, the Ministry of Health created, in 1993, the Program for Specialized Medicaments, where all the drugs included in this category were distributed for free through Clinics and Hospitals. During the first year of this Program's implementation, there were 15 different items distributed into 31 distinct presentations. Nowadays, the list expanded to 150 different items dispensed into 310 presentations. Hence, the availability of imported pharmaceutical products in Brazil overloaded the expenses by the Brazilian Ministry of Health. Only during 2011, US$ 1.5 billion were spent on these products, where 30% of this amount was related to specialized ones. In order to reduce costs, the Brazilian Federal Government developed, in 2004, the Technological Innovation Law. According to the Decree number 6.041, the National Politics for Biotechnology and the National Committee of Biotechnology were created in order to stimulate the development of Biotechnology for human health, targeting mainly the national production of biopharmaceuticals. Furthermore, the end of patents for several medicaments during the last 5 years enhanced the motivation for national production of new drugs. In this way, some Governmental Institutions, in partnership with International Pharmaceutical Industries, started developing the first biosimilar molecules. Therefore, this report describes the evolution of Biotechnology in Brazil, relating the laws, regulations and Programs created along the last 20 years for Human Health application.

show abstract

Analysis of similar drug labeling: potential medication errors

Cited by 8 publications

References 14 publications

Nursing errors in the media: patient safety in the window

Nursing errors in the media: patient safety in the window

Prevention strategies to identify LASA errors: building and sustaining a culture of patient safety

Biopharmaceutical and Biosimilar Products in Brazil: From Political To Biotechnological Overview

Contact Info

Product

Resources

About